# Special Issue

# Ovarian Cancer: From Mechanisms to Novel Target Therapies

## Message from the Guest Editor

Epithelial ovarian cancer (EOC) is the leading cause of gynecologic malignancy-related deaths worldwide. Despite advances in multidisciplinary treatment, the overall mortality has remained steady over the past thirty years. Most EOC patients are diagnosed at an advanced stage, and they eventually develop chemo-resistant relapsed disease despite surgery and combination chemotherapy. To date, the mechanism underlying chemo-resistance in ovarian cancer remains unclear. In addition, ovarian cancer falls under a heterogeneous group of malignancies that arise from various cell types, and the genetic mechanisms involved in chemo-resistance should be complex and differentially defined among different subtypes of ovarian cancer. Thus, to develop novel therapeutic strategies, it is crucial to define reliable predictive biomarkers for different subtypes and therapeutic resistance.

## Guest Editor

Dr. Yi-Hui Wu

Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan

## Deadline for manuscript submissions

closed (1 January 2025)

# Biomedicines

**an Open Access Journal by MDPI**

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/
biomedicines

## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

### Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

### Author Benefits

**High Visibility:**
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:**
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

**Rapid Publication:**
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).